NCT03473002View on ClinicalTrials.gov

A Safety and Immunogenicity Study of Intranasal Sendai Virus Vectored Respiratory Syncytial Virus (SeVRSV) Vaccine in Healthy Adults

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 16, 2018

Primary Completion Date

February 14, 2019

Study Completion Date

February 14, 2019

Conditions

Antiviral ProphylaxisRespiratory Syncytial Virus Infection

Interventions

OTHER

Placebo

0.9% Sodium Chloride

BIOLOGICAL

SeVRSV Vaccine

Recombinant Sendai virus vectored respiratory syncytial virus (SeVRSV) vaccine. SeVRSV is a replication-competent Sendai virus that carries the RSV F gene produced by reverse genetics technology.

Trial Locations (1)

45206-1613

Cincinnati Children's Hospital Medical Center - Infectious Diseases, Cincinnati

All Listed Sponsors

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT03473002 - A Safety and Immunogenicity Study of Intranasal Sendai Virus Vectored Respiratory Syncytial Virus (SeVRSV) Vaccine in Healthy Adults | Biotech Hunter | Biotech Hunter